What is Cambrian Bioworks?
Cambrian Bioworks specializes in automated solutions for genomic testing and molecular diagnostics, focusing on precision medicine in oncology, infectious disease diagnostics, and genetic testing. Their product offerings include systems for DNA/RNA extraction, library preparation, and digital microscopy, designed to enhance laboratory workflows. The company aims to empower labs by providing efficient and reliable tools that integrate seamlessly into existing operations. Their intended clients range from innovative research teams to high-throughput diagnostic centers. The company's focus on precision medicine and advanced diagnostics positions it as a key player in the rapidly evolving healthcare technology sector.
How much funding has Cambrian Bioworks raised?
Cambrian Bioworks has raised a total of $1.4M across 1 funding round:
Angel/Seed
$1.4M
Angel/Seed (2024): $1.5M, investors not publicly disclosed
What's next for Cambrian Bioworks?
With its recent major enterprise-level funding, Cambrian Bioworks is poised for significant expansion and further development of its automated genomic testing platforms. This strategic investment will likely fuel advancements in their product pipeline, enabling enhanced precision medicine capabilities in oncology and infectious disease diagnostics. The company's trajectory suggests a focus on scaling laboratory operations and broadening its market reach, solidifying its position as a provider of efficient and reliable tools for research and diagnostic centers.
See full Cambrian Bioworks company page
